Entries by SM

$MRTX target doubled by Citigroup

Citigroup reiterates buy on Mirati Therapeutics (MRTX) doubling the price target to $16. CIBC and Cann initiate coverage with outperform rating and target of $18. Check out more ratings on our SeekingAlpha Marketplace Daily Pharma Scoop.

$GERN is a true binary event for next year

Our daily analysis of a stock with a major event/upside: Geron’s potential with Imetelstat and its agonizingly slow progress towards the market Geron (GERN) imetelstat can potentially bring about a paradigm shift in non-solid cancer therapeutics. Imet inhibits telomerase, an enzyme that enables malignant cells to replicate with its DNA intact by protecting the ends […]

$AMGN and $AGN catalyst rundown

FDA approves Amgen and Allergan's MVASI™ (bevacizumab-awwb) for the treatment of five types of cancer. Approval based on totality of evidence from global development program showing MVASI™ is highly similar to Avastin® (bevacizumab). First ever biosimilar to fight cancer approved by FDA. Full catalyst rundown available in our daily pharma scoop at SeekingAlpha Marketplace page.

$SUPN good interim data

Supernus Pharmaceuticals (SUPN) came out with good interim data from a phase 3 study of SPN-810 for the treatment of impulsive aggression (IA) in children 6 - 12 years old. More news in our daily pharma scoop in our SeekingAlpha Marketplace page.

Insiders buy $LXRX $OPK $NBRV

Insider Purchases Ticker Company Insider Title Value Traded AGN Allergan Plc COB, Pres, CEO +$20,626 CASI Casi Pharmaceuticals, Inc. Dir +$419,178 EPZM Epizyme, Inc. Dir +$3,050,000 IRIX Iridex Corp COB, CEO +$16,956 LXRX Lexicon Pharmaceuticals, Inc. Pres, CEO +$376,337 LXRX Lexicon Pharmaceuticals, Inc. Dir +$12,500 NBRV Nabriva Therapeutics Plc 10% +$497,889 OPK Opko Health, Inc. […]

$NBRV target raised

Wedbush Reiterates Outperform on Nabriva Therapeutics AG (NBRV) raising target from $13 to $21. SunTrust Banks Raises Target from $20 to $24. Cantor Fitzgerald Reiterates Overweight with target of $16. Leerink Swann Reiterates Outperform raising target from $20 to $22. Check out more ratings on our SeekingAlpha Marketplace page.